Back to Research Hub
NewAmsterdam Pharma Company N.V.
NAMS
$30.38-0.57 (-1.84%)
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically…
StreetsValue research for NewAmsterdam Pharma Company N.V. (NAMS)
Members get the full report for NewAmsterdam Pharma Company N.V.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.